scholarly journals Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database

2021 ◽  
Author(s):  
George Kafatos ◽  
Victoria Banks ◽  
Peter Burdon ◽  
David Neasham ◽  
Caroline Anger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Braf Mutation ◽  
European Countries ◽  
High Prevalence ◽  
Biomarker Testing ◽  
Colorectal Cancer Patients ◽  
Over Time

Background: The literature on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results: RAS testing was conducted in >90% of mCRC patients from 2014 onwards. BRAF testing increased from 31% of mCRC patients in 2013 to 67% in 2018. MSI testing increased from 10 to 41%. There was no notable trend over time for RAS and BRAF mutation or MSI-high prevalence. Conclusion: Biomarker testing among patients diagnosed with mCRC was increased over time. This study demonstrates the quick uptake of biomarker testing in clinical practice. These findings are significant as biomarker-based drugs are becoming more common.

scholarly journals Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 393
Author(s):  
Alexander Hendricks ◽  
Anu Amallraja ◽  
Tobias Meißner ◽  
Peter Forster ◽  
Philip Rosenstiel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
High Risk ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Standard Of Care ◽  
High Risk Patients ◽  
Risk Patients ◽  
Individualized Treatments ◽  
Colorectal Cancer Patients

Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrospective study of metastatic colorectal cancer patients of confirmed European ancestry comprised 54 Americans and 54 gender-matched Germans. The Americans received standard of care, and on treatment failure, 35 patients received individualized treatments. The German patients received standard of care only. Tumor mutations, tumor mutation burden and microsatellite status were identified by using the FoundationOne assay or the IDT Pan-Cancer assay. High-risk patients were identified according to the mutational classification by Schell and colleagues. Results: Kaplan–Meier estimates show the high-risk patients to survive 16 months longer under individualized treatments than those under only standard of care, in the median (p < 0.001). Tumor mutation profiles stratify patients by risk groups but not by country. Conclusions: High-risk patients appear to survive significantly longer (p < 0.001) if they receive individualized treatments after the exhaustion of standard of care treatments. Secondly, the tumor mutation landscape in Americans and Germans is congruent and thus warrants the transatlantic exchange of successful treatment protocols and the harmonization of guidelines.

Efficacy, tolerability, and manageability of TAS-102 plus bevacizumab for metastatic colorectal cancer patients in clinical practice.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e15535-e15535
Author(s):  
Hideki Ishikawa ◽  
Koichi Suzuki ◽  
Nao Kakizawa ◽  
Fumiaki Watanabe ◽  
Kosuke Ichida ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

scholarly journals Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

2019 ◽  
Vol Volume 12 ◽  
pp. 2159-2170 ◽  
Author(s):  
Alessio Cortellini ◽  
Katia Cannita ◽  
Alessandro Parisi ◽  
Paola Lanfiuti Baldi ◽  
Olga Venditti ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Colorectal Cancer Patients ◽  
Intensive Regimen

scholarly journals Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis

PLoS ONE ◽  
2016 ◽  
Vol 11 (7) ◽  
pp. e0157751 ◽  
Author(s):  
Roberta Grande ◽  
Clara Natoli ◽  
Fabrizio Ciancola ◽  
Donatello Gemma ◽  
Arianna Pellegrino ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Multicenter Analysis ◽  
Colorectal Cancer Patients

Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: A systematic review and meta-analysis based on tumor sidedness and KRAS subtypes

2021 ◽  
pp. 1-10
Author(s):  
Khadijeh Saravani ◽  
Morteza Salarzaei ◽  
Fateme Parooie
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Braf Mutation ◽  
Meta Analysis ◽  
Tumor Location ◽  
Cochrane Library ◽  
Braf Mutations ◽  
The Right ◽  
Colorectal Cancer Patients

INTRODUCTION: Metastatic or recurrent colorectal cancer (MRCRC) has a poor prognosis. The aim of the present meta-analysis was to assess the prevalence of different subtypes of KRAS mutation and BRAF mutation in metastatic CRC patients, and evaluate the relationship between the tumor sidedness and prevalence of KRAS and BRAF mutation. METHODS: We searched MEDLINE/PubMed, the Cochrane Library, and ClinicalTrials.gov from January 2010 to July 2020. The data were extracted independently according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The statistical analysis was done using STATA and Meta-Disk 1.4 applications. RESULTS: Overall, 6699 colorectal cancer patients were included. KRAS and BRAF mutation was reported in 28% and 6% of patients, respectively. The overall prevalence of right primary and left primary metastatic CRC patients with mutated KRAS was 40% and 60%. However, the prevalence BRAF mutated right primary and left primary metastatic CRC patients was 37% and 63%. The overall HR was 2.38 for patients with metastatic CRC who had a mutated type of KRAS. Our study showed a mean overall survival of 35.4 month for KRAS mutant and a 10.12 month survival for BRAF mutant patients with metastatic colorectal cancer patients. CONCLUSION: The prevalence of KRAS and BRAF mutations varied significantly according to the location of the tumor. BRAF mutations are more commonly found in metastatic colorectal cancers on the right side. Liver was the most common site of metastases in patients with mutant KRAS and the mortality of patients with mutant KRAS was 2.3 times higher than the patients with wild types. These results help to better describe the population of mCRC patients and can have implications for improving and organizing anti-EGFR therapies. Further research is needed to assess differences in survival through mutation status and primary tumor location.

scholarly journals A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice

2018 ◽  
Vol 7 (1) ◽  
pp. CRC01 ◽  
Author(s):  
Beatrice Borelli ◽  
Gemma Zucchelli ◽  
Daniele Rossini ◽  
Chiara Cremolini ◽  
Carlotta Antoniotti ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
Retrospective Study ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document